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Abstract Evolving knowledge regarding sex differences
in coronary heart disease has demonstrated that the
prevalence, symptomatology, and pathophysiology of
coronary atherosclerosis vary between genders. Women
experience higher mortality rates and more adverse out-
comes after acute myocardial infarction than men, de-
spite a lower prevalence of obstructive coronary artery
disease. Based on recent insights into the complex path-
ophysiology of coronary heart disease which includes a
spectrum of obstructive coronary artery disease and
dysfunction of the coronary microvasculature and endo-
thelium, the term ischemic heart disease is a more
accurate term for discussion of coronary atherosclerosis
specific to women. In women, with clinical features and
risk factors for ischemic heart disease, the detection and
evaluation of ischemic heart disease is challenging due
to the diverse pathogenic mechanisms of ischemic heart
diseases in women. In this article, we discuss noninva-
sive imaging tests, provocative tests, including exercise
testing in women with suspected ischemic heart disease.
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Introduction
Marked reductions in cardiovascular mortality in women
have occurred for the first time in the past decade due to
an increase in awareness, greater focus on prevention strat-
egies as well as the application of evidence-based treatments
for established coronary artery disease (CAD) [1–3]. De-
spite this progress, CAD is still the leading cause of death
and disability in the United States, claiming the lives of
almost 200,000 women every year [4–7]. The focus on
sex-specific cardiovascular disease research has greatly im-
proved our understanding of the pathophysiology of coro-
nary disease in women [4]. The Women’s Ischemia
Syndrome Evaluation (WISE) trial and related studies have
expanded our understanding of the complex pathophysiolo-
gy of coronary atherosclerosis in women to include abnor-
mal coronary reactivity [8], microvascular dysfunction [9],
and plaque erosion/distal microembolization [10, 11], as
contributory factors to a female sex-specific ischemic heart
disease [12•, 13, 14••]. Although prior evidence supports the
fact that atherosclerotic plaque impeding forward flow in a
coronary artery is the primary etiology of symptoms,
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morbidity, and mortality for coronary artery disease, data
from the WISE trial elucidated a new paradigm for ischemic
heart disease in women. In a cohort of the WISE women,
chest pain and abnormal stress tests occurred without a
critical (flow-limiting) lesion and at 5-year follow-up, these
women had an intermediate risk of cardiovascular events.
The WISE study provides prognostic information on symp-
tomatic women with nonobstructive disease. In these women,
symptoms persisted in the setting of usual anti-anginal thera-
py and during 5-year follow-up, there was an increased rate of
cardiac mortality, myocardial infarction, stroke, and hospital-
ization for congestive heart failure for the 33 % of symptom-
atic women with angiographically normal or nonobstructive
coronary stenoses compared with a similarly matched cohort
of women without symptoms [15]. Endothelial dysfunction
and microvascular disease was felt to be the cause of persis-
tent symptoms and abnormal stress tests in this group of
WISE women [14••].
Additional data reveal that younger and middle aged
women with acute MI are more likely to have a poorer
prognosis and higher mortality compared with their male
counterparts [16–18], and that in over 50 % of symptomatic
women undergoing cardiac catheterization for acute coro-
nary syndrome (ACS), no evidence for obstructive CAD is
found [14••]. Recent data have added to our understanding
of the mechanism of ACS in women in the absence of focal
areas of stenosis. Intravascular ultrasound and cardiac mag-
netic resonance (CMR) were used to demonstrate evidence
of plaque disruption and myocardial damage among women
with confirmed acute myocardial infarction (AMI) and nor-
mal or only minimally abnormal coronary angiograms [12•,
19]. In women, the dynamic interaction of hormonal fluctu-
ations, risk factors, and differences in vascular structure and
function contribute to the development of a somewhat dif-
ferent form of ischemic heart disease (IHD) disease with
small coronary arteries, diffuse disease, and microvascular
dysfunction being seen more frequently among women [4,
7, 14••]. Given the expanded milieu of coronary atheroscle-
rosis in women, the term ischemic heart disease (IHD) is
proposed as a more accurate and inclusive term for the
spectrum of coronary atherosclerosis specific to women,
rather than CAD or coronary heart disease (CHD) [14••].
These new data pave the way for an expanded role of
cardiac imaging to investigate other elements implicated in
the spectrum of IHD in women—the coronary and noncoro-
nary atherosclerotic burden andmethods to detect dysfunction
of the coronary endothelium, flow reserve, and microvascu-
lature—as these factors have increasingly significant implica-
tions for diagnosis, prognosis, and treatment [7, 14••].
Therefore, early identification of women at risk for ische-
mic heart disease is critical, especially given that sudden
cardiac death is often the first manifestation of IHD in a high
proportion of women (52%), comparedwithmen (42%) [20].
We review the literature on the role of contemporary and
emerging techniques for the diagnostic and prognostic eval-
uation of symptomatic women at risk for ischemic heart
disease.
The Role of Contemporary Testing Techniques
for Diagnosis and Risk Assessment of Symptomatic
Women at Risk for Ischemic Heart Disease
Exercise Electrocardiogram (ECG)
Exercise stress testing is the most commonly used method of
diagnosing IHD in women and is the initial noninvasive study
of choice. As per the American College of Cardiology/Amer-
ican Heart Association guidelines, nonimaging treadmill ex-
ercise stress testing (ETT) continues to be an appropriate first
line testing symptomatic women who are (1) deemed inter-
mediate risk for IHD, (2) have a normal resting 12-lead ECG,
and (3) are capable of maximal exercise [21–23]. Although
historical evidence suggests a lower sensitivity and specificity
of ETT for the detection of epicardial disease, recent research
has improved our understanding of the diagnostic and prog-
nostic value of this modality in women [24•].
Lower exercise tolerance of women and the use of tradi-
tional criteria for a positive ETT of ≥1 mm horizontal or
downsloping reversible ST-segment depressions result in an
underdiagnosis of obstructive coronary disease. In a meta-
analysis of 3721 women being evaluated for IHD with an
ETT, positive ECG changes were shown to have a sensitiv-
ity and specificity in women of 61 % and 70 %, respectively
[25], compared with men where both sensitivity and speci-
ficity have been shown to be approximately 10 % higher
[14••]. The accuracy for detecting obstructive CAD is de-
pendent on the magnitude, morphology, and duration of the
ECG changes. Marked ST-segment changes (ie, ≥2 mm
horizontal or downsloping ST depression at low workloads
and persisting into recovery) are more sensitive markers for
epicardial disease in women [26].
The strength of the ETT lies in its ability to provide
important prognostic data on the risk of cardiac death or
myocardial infarction in women. The diagnostic and prog-
nostic accuracy of exercise testing in women can be im-
proved by incorporating parameters such as exercise
capacity, chronotropic response, heart rate recovery, blood
pressure response, and the Duke Treadmill Score (DTS), in
addition to ST-segment depression with exercise [24•]. The
DTS is defined as exercise time, (5×ST segment deviation),
4×chest pain (1 0 nonlimiting, 2 0 limiting) [27]. Duration
of metabolic equivalents (METs) is the strongest prognostic
variable from treadmill ETT [28, 29] with a higher death
rate in women who can achieve less than 5 METS compared
with those able to achieve more than 8 METs [30].
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The powerful prognostic role of exercise capacity as
determined by the ETT was validated in the recent publica-
tion of the prospective, randomized clinical trial “What is
the Optimal Method for Ischemic Evaluation in Women
(WOMEN) Trial.” In the cohort of 824 symptomatic women
who were randomized to exercise treadmill test or exercise
stress myocardial perfusion imaging, no difference in out-
comes at 2 years was demonstrated in these symptomatic
women with suspected epicardial disease and who were able
to exercise [31••].
Therefore, exercise ECG is the test of choice for a symp-
tomatic woman with a normal ECG who is capable of achiev-
ing 5 METS or more. The use of the Duke Activity Status
Index (DASI) can help predict functional capacity. The DASI
score, a weighted scoring system that uses a 12-question
survey, has been validated in women to estimate the METs
associated with the activities of daily living. When DASI was
used in the WISE trial, there was an increased risk of cardio-
vascular death and nonfatal MI in women with a calculated
DASI score of less than 5 METs [19].
The Role of Stress Echocardiography
Contemporary stress echocardiography utilizing exercise or
dobutamine can be used to identify stress-induced ischemia
based on the development of regional wall motion abnor-
malities in the area of a decrease in myocardial blood flow.
Its role in symptomatic women at risk for ischemic heart
disease has been well established. Cumulative data analysis
of over 1000 women has shown the mean sensitivity of
stress echocardiography to detect physiologically significant
coronary disease to be 81 %, with a specificity of 86 % [22,
27, 32]. Sensitivity range 75 %–93 % and specificity range
79 %–92 % to reliably detect multi-vessel disease with
dobutamine stress echocardiography in women who are
unable to exercise [22].
Stress echocardiography has been shown to be useful for
determining cardiovascular prognosis in women [27–29]. In
a study evaluating 5-year survival in 4234 women undergo-
ing exercise stress echocardiography, survival in patients
with no evidence of ischemia was found to be as high as
99.4 % [29]. Survival was found to be 97.6 % in women
with evidence of single vessel ischemia and 95 % in women
with evidence of multiple-vessel ischemia [29]. Although an
abnormal stress echocardiogram correlates with a high car-
diac event rate in women, a recent meta-analysis comparing
dobutamine stress echocardiography to exercise single pho-
ton emission computed tomography (SPECT) myocardial
perfusion imaging (MPI) revealed a yearly rate of 0.75 %
of cardiovascular death and MI in the setting of a low-risk
dobutamine echocardiogram, compared with 0.3 % per year
in low-risk stress MPI [33]. The authors concluded that
stress echocardiography may underestimate risk in women
with less advanced CAD because perfusion abnormalities
detected by SPECT MPI precede the wall-motion abnormal-
ities detected by stress echocardiography. Wall motion ab-
normalities often occur in the setting of advanced stenosis
and less predictably in myocardium supplied by mild-to-
moderate coronary artery stenoses. Therefore, because an
MI often presents in myocardial areas perfused by a less
critical stenosis, stress echocardiography may underestimate
cardiovascular risk in women with nonobstructive CAD [33].
The added imaging information provided by stress-
echocardiography provides improved diagnostic and prog-
nostic accuracy in women at risk for CAD compared with
clinical variables and data from exercise treadmill testing
[32]. In addition, a unique benefit of stress echocardiogra-
phy for evaluating at-risk women is the absence of radiation
exposure compared with other noninvasive imaging techni-
ques (eg, SPECT, cardiac CT, coronary artery calcium scor-
ing). Incremental data (ie, valvular function pericardial
abnormalities) provided from a complete echocardiogram
may also reveal an alternative explanation for symptoms
of dyspnea or chest pain.
Myocardial Perfusion Imaging with SPECT
Myocardial Perfusion Imaging with Single Photon Emission
Tomography with ECG gating (MPI) provides quantitative
information on myocardial perfusion, regional and global
left ventricular function, and end-systolic and end diastolic
volumes. The diagnostic and prognostic value of contempo-
rary MPI techniques in evaluation of symptomatic women at
risk for CAD has been supported by data [22, 34, 35]. The
commonly seen limitations of traditional MPI techniques,
including photon attenuation due to breast attenuation arti-
fact and limited spatial resolution where minor perfusion
defects may go undetected in smaller hearts [35, 36], are less
problematic with the addition of electrocardiographic gat-
ing, attenuation correction protocols, use of prone imaging,
and use of higher-energy radioisotope technetium [22,
37–39]. For the diagnosis of physiologically significant
CAD in symptomatic women, the sensitivity of exercise
contemporary MPI techniques ranges from 78 % to 88 %,
with a specificity of 64 % to 91 % [37, 40].
An important advantage of MPI is the ability to use
pharmacologic stress for at- risk patients who are unable to
exercise or achieve an acceptable maximum heart rate with
exercise. Pharmacologic vasodilator MPI has been shown to
be accurate in detecting physiologically significant CAD in
women with a sensitivity and specificity for coronary ste-
nosis >50 % of 91 % and 86 %, respectively [41]. The
importance of pharmacologic stress is relevant in daily
clinical practice as very often, at-risk women are generally
older and often have reduced exercise capacity when they
present for evaluation. A large body of evidence supports
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the excellent prognostic accuracy of exercise and pharma-
cologic stress MPI in both men and women with the size and
severity of defects directly linked to the risk of cardiac even
independent of gender [35, 36, 42, 43].
The addition of gated left ventricular ejection fraction and
left ventricular volume to perfusion data further enhances
risk stratification [37, 38, 44, 45]. Pooled data in over 7000
women demonstrate an annual cardiac event rate of 0.7 %
with a normal perfusion study [46]. Based on the available
evidence, stress MPI is recommended for symptomatic
women with an intermediate to high pretest likelihood of
CAD with an abnormal, equivocal, or nondiagnostic base-
line ECG. Pharmacologic stress is recommended for symp-
tomatic women with normal or abnormal baseline ECG who
are unable to exercise or unable to achieve maximum pre-
dicted target heart rate with exercise [45]. Stress MPI with
exercise or pharmacologic stress adds incremental data to
clinical variables and stress ECG data in symptomatic wom-
en at risk for IHD [43].
Diagnostic Testing for Coronary Atherosclerosis:
Beyond Epicardial Disease
For the symptomatic woman with a positive stress test and
evidence of nonobstructive disease on coronary angiogra-
phy, additional diagnostic testing may be warranted.
Insights from clinical trials in the past decade have provided
evidence to support the fact that several mechanisms con-
tribute to worse outcomes and continued symptoms in the
cohort of women who have no evidence of obstructive CAD.
Microvascular dysfunction of the coronary bed may in
part account for the paradoxical finding of a greater symp-
tom burden and high cardiac mortality in these women with
a lower burden of obstructive CAD [14••]. Endothelial and
smooth muscle cell dysfunction contribute to a microvascu-
lar disorder frequently observed in women with signs and
symptoms of IHD and angiographically normal coronary
arteries. Several theories have been proposed to explain
normal angiographic results in women with chest pain. They
include chest pain of noncardiac origin, coronary artery
spasm, and diffuse disease without focal obstruction [47].
Higher rates of hypertension, left ventricular hypertrophy,
and diabetes in women are hypothesized to result in a
greater degree of microvascular disease in women compared
with men with similar degrees of epicardial stenosis [14••,
15]. In the coronary tree, both endothelial-independent
(microvascular) dysfunction and endothelial-dependent epi-
cardial dysfunction have been shown to predict worse IHD
events in patients undergoing diagnostic cardiac angiogra-
phy, single-vessel percutaneous coronary angioplasty (PCI),
or post ACS/MI [14••]. The identification of abnormalities
in the coronary tree has implications in treatment strategies
as restoration of endothelial function is associated with
improved outcome. Improved endothelial function was as-
sociated with a 7.3-fold lower rate of cardiac events in a
cohort of 400 hypertensive postmenopausal women, com-
pared with women with no improvement [48]. Therefore,
tests of vascular and endothelial integrity may help to dem-
onstrate vascular dysfunction and identify women at high
risk for cardiovascular outcomes [14••, 47]. Emerging data
from contemporary imaging techniques with protocols and
methods for the detection of subclinical atherosclerosis and
endothelial dysfunction promise to reveal a new model for the
identification and risk stratification of IHD in women [14••].
As we shift our focus from the detection of flow-limiting
CAD lesions, cardiac imaging techniques with cardiac CT,
positron emission tomography (PET), and CMR are emerg-
ing as techniques to investigate other contributors implicat-
ed in the spectrum of IHD in women—the coronary and
noncoronary atherosclerotic burden. Also, other methods
are being used with increasing frequency to detect dysfunc-
tion of the coronary endothelium and microvasculature.
Coronary Artery Calcium Scoring and Computed
Tomographic Angiography
Multi-slice computed tomography (CT) scanning with coro-
nary artery calcium (CAC) scoring and computed tomograph-
ic angiography (CTA) allow for a noninvasive anatomic
identification and quantification of obstructive and nonob-
structive CAD. CAC detection adds incremental prognostic
value to traditional cardiac risk factors for coronary artery
disease [43, 49]. In an asymptomatic cohort of 4191 women
and 6186 men, CAC was associated with a higher incidence
of death in women than in men at each level of calcification:
80 % of women with extensive coronary calcification and
CAC scores of more than 1000 were alive at 5-year follow-up
compared with 98.4 % of women with no evidence of CAC
[45]. CAC scoring is also highly sensitive for the presence of
obstructive CAD (≥50% stenosis) and provides an estimate of
the total calcified atherosclerotic plaque burden, thereby cor-
relating to a patient’s cardiac risk [50]. Sex-specific analysis
of the role of CAC in evaluating symptomatic women at risk
for coronary disease reveals a high negative predictive value
when correlated with invasive coronary angiography. Of 539
symptomatic women who underwent clinically indicated cor-
onary angiography, 41 % had a normal angiogram without
evidence of CAC, demonstrating a negative predictive value
of 100 %. There was a greater prevalence of obstructive CAD
in women with CAC scores of more than 100 [45].
Recent data reveal an evolving role for cardiac CT in the
identification and risk stratification of CAD in women at
risk for coronary disease [45, 51]. CTA allows for a nonin-
vasive evaluation of the coronary arteries with high diag-
nostic accuracy for obstructive epicardial CAD [52, 53]. In a
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series of 51 women and 52 men, the diagnostic sensitivity
and specificity was similar by sex at 85 % and 99 %,
respectively [54]. However, one of the important limitations
of CTA, particularly in young women, is the potential in-
crease in lifetime risk of cancer due to concentrated ionizing
radiation to radiosensitive breast tissue [55]. Consequently,
considerable efforts in dose reduction strategies are being
employed in order to reduce radiation while optimizing
diagnosis of atherosclerosis in symptomatic patients at risk
for CAD [56, 57].
Myocardial Perfusion Imaging with Positron Emission (PET)
MPI with PET is a robust nuclear medicine imaging tech-
nique, and with its superior spatial resolution improves on
the diagnostic and prognostic accuracy for detecting epicar-
dial CAD in both men and women. Given the spectrum of
IHD in women, an enhanced value to PET is the ability to
calculate absolute blood flow in all areas of the coronary
tree, assess wall motion at peak hyperemia with vasodilator
stress, and evaluate coronary flow reserve, thereby interro-
gating the coronary microvasculature and endothelium
[58–60]. The capacity to quantify myocardial perfusion
provides an added advantage over SPECT for evaluating
multi-vessel CAD [60, 61]. Multiple studies have performed
direct comparison of the diagnostic accuracy of 82Rb myo-
cardial perfusion PET and 201Tl or 99mTc SPECT. Their
overall results showed a high sensitivity of 90 %, high
specificity of 86 % and diagnostic accuracy of 90 % with
PET [60, 61]. Vasodilatory stress MPI with PET using
nuclear tracer 82Rb allows for integrated photon attenuation
correction and enhanced image quality, a notable advantage
over SPECT, when evaluating CAD in obese women. The
use of the isotope 82Rb PET is additionally beneficial in
women due to the ability to accurately quantify absolute
values of regional and global myocardial blood flow to
assess microvascular disease (flow reserve) [39]. Moreover,
contemporary integrated hybrid PET/CT offers an opportu-
nity to assess the presence and magnitude of subclinical
atherosclerotic disease burden and to further investigate
myocardial blood flow as a marker of endothelial function
and atherosclerotic disease activity which is of paramount
importance in female patients [60].
As with SPECT, increasing extent and severity of perfu-
sion defects with stress PET is associated with increasing
frequency of adverse events. The overall event rate in
patients with normal stress PET was 0.4 % per year [60].
A recent study on a cohort of 1432 patients followed for
1 year after 82Rb PET MPI with vasodilatory stress was
shown to be a powerful predictor of cardiac event and
survival in patient with known CAD or an intermediate to
high pretest likelihood of CAD [58]. Myocardial perfusion
imaging added incremental value to LVEF (ie, at any LVEF,
a higher summed stress score had greater risk) and LVEF
added incremental value to myocardial perfusion imaging
(ie, at any summed stress score, a lower LVEF had greater
risk). Furthermore, LVEF reserve independently provided
significant and incremental value over perfusion for predict-
ing future risk of adverse events [58, 60].
With its ability to detect epicardial disease as well as
evaluate the coronary microvasculature and endothelium,
this technology is an important advance in imaging, specif-
ically for imaging of CAD in women. Future investigations
of the potential complementary role of CTA and PET per-
fusion imaging for risk stratification and management of
women with IHD promise to expand PET’s role to include
an evaluation of the atherosclerotic burden.
Cardiac Magnetic Resonance Imaging (CMR)
Cardiac magnetic resonance imaging (CMR) is emerging as
an important imaging modality for the diagnosis of CAD in
women. CMR allows for the differentiation of a range of
myocardial diseases ranging from ischemic heart disease to
nonischemic cardiomyopathies, including stress-induced
cardiomyopathy (takotsubo) [62–65]. CMR perfusion has
the unique ability to evaluate subendocardial ischemia, as-
sess left and right ventricular function, and provide a de-
tailed anatomic evaluation of both the myocardium as well
as of the peripheral vasculature. The specific advantages to
the use of CMR imaging for the evaluation of women with
suspected CAD is its excellent soft tissue characterization,
three-dimensionality, superior temporal and spatial resolu-
tion, and lack of ionizing radiation [4, 66].
Dobutamine CMR has been studied to identify flow limit-
ing coronary artery stenoses in women [66]. In a study of a
cohort of 266 women, inducible left ventricular wall motion
abnormalities during dobutamine CMR predicted cardiac
death and MI in women with known or suspected ischemic
heart disease [67]. Although data sets are small, the results
suggest that dobutamine CMR is a valuable noninvasive stress
imaging modality for identifying disease in at-risk women,
with a sensitivity and specificity for detecting obstructive
CAD in women of 85 % and 86 %, respectively [68].
CMR with vasodilator stress (dipyridamole or adenosine)
has also been used to detect myocardial ischemia through
first-pass perfusion imaging [69–73]. Ischemic territories
can be identified through intravenous dipyridamole and
gadolinium for first-pass perfusion and an estimation of a
myocardial perfusion reserve index. In a small study of 48
patients and 18 healthy subjects, a coronary flow reserve
less than 1.65 had a sensitivity and specificity of 91 % and
94 % percent, respectively, for the detection of coronary
artery disease as defined by PET scanning [72].
There is growing evidence on the prognostic ability of
CMR in symptomatic women at risk for IHD. In one of the
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first reports assessing the prognostic value of CMR with
adenosine and dobutamine, 513 patients were evaluated dur-
ing a mean follow-up of 2.3 years [74]. The 3-year event-free
(cardiac death and nonfatal myocardial infarction) survival
was 99 % with normal and 84 % with abnormal combined
stress images. CMR has added value for symptomatic women
who are found to have nonobstructive or normal coronaries on
invasive angiography. Due to its excellent temporal and spa-
tial resolution, CMR with perfusion has the ability to identify
subendocardial ischemia and may provide an etiology for
women with persistent chest pain without obstructive CAD
[66]. In addition, CMR has the ability to detect prior or recent
myocardial infarctions with high sensitivity, which may be
silent or unsuspected in women who are at risk.
Additional Emerging Imaging Techniques for Detection
of IHD in Women
Emerging innovative techniques have the ability to provide
semiquantitative information of coronary flow, with slow
flow in the absence of significant stenosis reflect impair-
ment of the myocardial microcirculatory perfusion [75]. The
use of intravascular coronary ultrasound and intracoronary
Doppler flow wire has essentially replaced the use of acetyl-
choline infusion for the evaluation of endothelial function.
Coronary flow can be studied invasively in the cardiac cath-
eterization laboratory by using intracoronary Doppler wires or
by the thrombolysis in myocardial Infarction frame count to
measure flow [76]. For the woman with ischemic symptoms,
an abnormal stress test with no evidence of flow-limiting
stenoses on standard angiography, intravascular ultrasonogra-
phy, or intracoronary Doppler flowmay document atheroscle-
rosis within the arterial wall. This is relevant as significant
“outward remodeling” remodeling, atherosclerotic lesions that
protrude outward rather than impinging on the lumen as seen
in classic obstructive disease) with impaired coronary flow
reserve or endothelial dysfunction has been noted to occur
more frequently in women and be the cause of symptoms [11].
Emerging noninvasive methods for the detection of en-
dothelial dysfunction in addition to those discussed above
include high-frequency transthoracic Doppler harmonic
echocardiography, transesophageal echocardiography with
Doppler imaging, and digital reactive hyperemia peripheral
arterial tonometry [77]. Brachial artery reactivity testing
offers a window to study the integrity of the coronary
endothelium and can be used to noninvasively detect endo-
thelial dysfunction as impaired brachial endothelial function
is associated with increased cardiovascular adverse events.
Recent evidence point to the presence of atherosclerosis in
the peripheral vasculature as highly correlated with coronary
atherosclerosis. The use of ABI and CIMT are noninvasive
Fig. 1 Adapted with permission from Phillips L.M. Noninvasive Assessment of Coronary Artery Disease in Women: What’s Next?. Curr Cardio
Reports. 2010;12:152
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imaging modalities that can be used for detection of peripheral
atherosclerosis as a surrogate for CAD in asymptomatic wom-
en at risk for IHD [14••].
Recommendations
It is important for clinicians to appreciate that althoughwomen
have a higher atherosclerotic burden, are more symptomatic,
and have a worse clinical outcome, they have a lower preva-
lence of obstructive coronary disease than men. The patho-
physiology of heart disease in women is a spectrum and,
therefore, the clinician must consider a unique evaluation
approach, which in some case will extend beyond the detec-
tion of epicardial stenosis to include evaluation of the athero-
sclerotic burden as well as an evaluation of coronary reactivity
of the microvasculature and endothelium.
Clinicians must evaluate risk factors, symptoms, and
baseline ECG in women with risk factors for IHD to estab-
lish their pretest likelihood of disease. Next, an assessment
of the patient’s functional capacity is important to assess
prognosis, but also to appropriately choose the best nonin-
vasive stress testing modality. Current evidence supports the
use of the exercise ECG stress test as the initial test for
symptomatic women with a normal resting ECG and good
exercise tolerance (capable of >5 METS). The calculation of
functional capacity and clinical scores such as the Duke
Treadmill Score further improve the ability to diagnosis
and to assess prognosis in women [4, 22].
Cardiac imaging with stress MPI or stress echocardiogra-
phy provides incremental information over clinical variables
and the exercise ECG in symptomatic women with suspected
CAD. Local expertise should guide selection of the test.
According to the American Heart Association consensus
statement, symptomatic women with questionable exercise
capacity, abnormal baseline ECG, and those with diabetes
mellitus, should undergo cardiac imaging with exercise or
pharmacologic stress as the initial test in the evaluation of
symptoms [24•]. Evolving evidence supports the use of newer
techniques like CTA in the setting of an abnormal or equivocal
stress cardiac imaging study. PET and CMR are other newer
methods that can be very useful in symptomatic women with
no evidence of obstructive CAD to evaluate the coronary
microvasculature for evidence of subendocardial ischemia or
abnormal coronary reserve (Fig. 1).
Conclusions
Insights from recent clinical trials have provided evidence
that there are clear gender differences that exist in the
pathophysiology, clinical presentation, diagnosis, and treat-
ment of CAD. The etiology of IHD in women is
multifactorial and includes a spectrum from obstructive
epicardial CAD to nonobstructive CAD with dysfunction
of the coronary microvasculature and endothelium. Future
imaging protocols that focus on analyzing endothelial func-
tion and detection of subclinical atherosclerosis will likely
be integrated into diagnostic and prognostic algorithms for
at-risk women. Emerging novel technologies and protocols
using CMR, assessment of carotid intima-media thickness,
and brachial artery flow-mediated dilatation will be useful to
further identify atherosclerotic burden and define the unique
pathophysiology of ischemic heart disease in symptomatic
women without evidence of obstructive CAD.
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